Although tumors in the MYC-low ER+ PDX model responded well to navitoclax as a single agent (we note that BCL-2 expression is often reported as enriched in this breast cancer subtype30), combining it with metformin did not offer any added benefit (Supplementary Figure 5F). Here, MYC is linked to breast carcinoma.